Quality control limits for microdilution susceptibility tests with aztreonam, imipenem, ceftriaxone, ceftazidime, ceftizoxime, cefuroxime, and cefonicid.
A six-laboratory collaborative study was performed in order to define quality control limits for microdilution tests with seven new beta-lactams (aztreonam, imipenem, ceftriaxone, ceftazidime, ceftizoxime, cefuroxime, and cefonicid). Four standard control strains were tested and the expected MIC limits for each of the appropriate drug-microorganism combinations were defined.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001398:Aztreonam / Q000494:pharmacology; D002435:Cefamandole / Q000031:analogs & derivatives / Q000494:pharmacology; D015790:Cefonicid; D002439:Cefotaxime / Q000031:analogs & derivatives / Q000494:pharmacology; D002442:Ceftazidime / Q000494:pharmacology; D015296:Ceftizoxime; D002443:Ceftriaxone / Q000494:pharmacology; D002444:Cefuroxime / Q000494:pharmacology; D013293:Enterococcus faecalis / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects; D015378:Imipenem; D008826:Microbial Sensitivity Tests / Q000592:standards*; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D011786:Quality Control; D013845:Thienamycins / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D013845:Thienamycins; D002435:Cefamandole; D015790:Cefonicid; D015378:Imipenem; D002443:Ceftriaxone; D002442:Ceftazidime; D015296:Ceftizoxime; D001398:Aztreonam; D002439:Cefotaxime; D002444:Cefuroxime